Cartalax 20mg

Cartalax is a synthetic short bioregulatory peptide composed of three amino acids (Ala–Glu–Asp, “AED”) that targets fibroblasts across various tissues—including skin, cartilage, kidneys, and blood.
 
It modulates cellular aging markers by boosting proliferation factors like Ki‑67, downregulating p53/p16/p21, reducing apoptosis via caspase‑3 inhibition, and normalizing extracellular matrix enzymes such as MMP‑9.
Cartalax also appears to enhance mitochondrial resilience to oxidative stress, support energy homeostasis, and regulate cytokine.  These effects help rejuvenate older, senescent cells, restoring structural integrity and function to connective tissues, data suggest applications in joint and cartilage health—including cartilage repair, inflammation reduction, and improved mobility—as well as broader geroprotective benefits. On going research continues to explore its mechanisms and therapeutic potential across age‑related and degenerative conditions.
Today, Cartalax is most commonly used in preclinical research and wellness practices aimed at connective tissue and joint support. It’s available in lyophilized powder form for laboratory studies and capsulated formulas marketed as dietary supplements targeting cartilage, bone, and joint health. Some clinicians and biohackers also utilize sublingual or injectable versions in short treatment cycles (typically 10–30 days) to support joint mobility, reduce inflammation, and enhance tissue repair